Table 4.

Descriptive statistics of pharmacokinetic variables of deconjugated bivatuzumab mertansine after a 3-week once weekly infusion regimen (n = 7, weeks 1 and 2; n = 6, week 3)

WeekAUC0-168* [(μg · h/mL)/(mg/m2)]Cmax* [(μg/mL)/(mg/m2)]tmax [h]t1/2 [h]
1gMean13.30.11148.6183
gCV (%)24.023.147.3-12038.5
2gMean20.80.16647.5166
gCV (%)21.219.16.03-73.332.1
3gMean23.80.18736152
gCV (%)20.119.721.7-73.310.4
  • * Dose normalized.

  • Median and range.

  • Variables at steady-state (ss).